Lates News

Each NetEase headline AI, the open-source securities released a research report on June 15, giving a buy rating to Yuekang Pharmaceutical (688658.SH). The rating reasons mainly include: 1) comprehensively layout multiple technology platforms and full-chain research and development system, innovation leading long-term development; 2) YKYY015 is the only pipeline drug in the clinical stage of domestic PCSK9siRNA approved for IND in the United States; 3) focusing on high-barrier core patent technology, enhancing the forward-looking and competitiveness of mRNA pipeline. (Daily Economic News)